COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Product Liability Contingency [Line Items]
Net sales
License agreement description			(1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial DNA), Enviro is obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement, (2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses or terminate the licenses.
Non-US [Member] | Food and Drug Administration [Member]
Product Liability Contingency [Line Items]
Payment for milestone			$ 1,500
Phase I Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment for milestone			150
Item 1 And 2 [Member] | Phase II [Member]
Product Liability Contingency [Line Items]
Payment for milestone			250
Item 3 [Member] | Phase II Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment for milestone			500
Item 1, 2 and 3 [Member]
Product Liability Contingency [Line Items]
Payment for milestone			250
Net sales			5,000
Item 4 [Member]
Product Liability Contingency [Line Items]
Payment for milestone			2,500
Net sales			50,000
Item 4 [Member] | Food and Drug Administration [Member]
Product Liability Contingency [Line Items]
Payment for milestone			1,500
Item 4 [Member] | Phase II Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment for milestone			250
Item 4 [Member] | Phase I Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment for milestone			150
Exclusive License Agreement [Member]
Product Liability Contingency [Line Items]
License fee			5
Annual maintenance fee			$ 10
Royalty percentage			3.75%
Exclusive License Agreement [Member] | Item 4 [Member]
Product Liability Contingency [Line Items]
License fee			$ 50
Annual maintenance fee			$ 10
Royalty percentage			4.25%
Minimum requirerment of capital	$ 500		$ 500
Patent product sales			0.50%
Exclusive License Agreement [Member] | Minimum [Member]
Product Liability Contingency [Line Items]
Patent protection costs			$ 9
Other non-royalty sublicense fees percentage			5.00%
Exclusive License Agreement [Member] | Minimum [Member] | Item 4 [Member]
Product Liability Contingency [Line Items]
Other non-royalty sublicense fees percentage			5.00%
Exclusive License Agreement [Member] | Maximum [Member]
Product Liability Contingency [Line Items]
Patent protection costs			$ 61
Other non-royalty sublicense fees percentage			35.00%
Exclusive License Agreement [Member] | Maximum [Member] | Item 4 [Member]
Product Liability Contingency [Line Items]
Other non-royalty sublicense fees percentage			35.00%
Enviro Cedars License Agreements [Member] | Item 1 And 2 [Member] | Phase III [Member]
Product Liability Contingency [Line Items]
Net sales			$ 100,000
Enviro Cedars License Agreements [Member] | Phase III Clinical Trial [Member]
Product Liability Contingency [Line Items]
Net sales			$ 50,000